Adrienne G. Waks
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Adrienne G. Waks sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Adrienne G. Waks: 4 sponsored US clinical trials, 1 recruiting.
Adrienne G. Waks sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 3 trials.
Upper-quartile sponsor footprint
Adrienne G. Waks sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT03414658
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT02999477
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
What is open in the Adrienne G. Waks pipeline
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (3 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Adrienne G. Waks: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Adrienne G. Waks sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Adrienne G. Waks page
4 registered trials is a research-attention snapshot, not an endorsement of Adrienne G. Waks or any single study.
- 1 of Adrienne G. Waks's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Adrienne G. Waks studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Adrienne G. Waks pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.